bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Authors: Audenet François , Isharwal Sumit , Cha Eugene K. , Donoghue Mark T.A. , Drill Esther N. , Ostrovnaya Irina , Pietzak Eugene J. , Sfakianos John P. , Bagrodia Aditya , Murugan Paari , Dalbagni Guido , Donahue Timothy F. , Rosenberg Jonathan E. , Bajorin Dean F. , Arcila Maria E. , Hechtman Jaclyn F. , Berger Michael F. , Taylor Barry S. , Al-Ahmadie Hikmat , Iyer Gopa , Bochner Bernard H. , Coleman Jonathan A. , Solit David B.
Published: April 2023

Oncoprints and Venn diagrams for matched-pair comparisons between UCB and UTUC samples in patients with a history of a prior bladder tumor before resection of the UTUC. The arrows show the time between sample collection in months.
Suppl. Figures legends from Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status
Authors: Cea Michele , Cagnetta Antonia , Acharya Chirag , Acharya Prakrati , Tai Yu-Tzu , Yang Cao , Lovera Davide , Soncini Debora , Miglino Maurizio , Fraternali-Orcioni Giulio , Mastracci Luca , Nencioni Alessio , Montecucco Fabrizio , Monacelli Fiammetta , Ballestrero Alberto , Hideshima Teru , Chauhan Dharminder , Gobbi Marco , Lemoli Roberto M. , Munshi Nikhil , Treon Steven P. , Anderson Kenneth C.
Published: April 2023

Suppl. figure legends
Figure S2 from Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer
Authors: Liu Jin , Agopiantz Mikaël , Poupon Joël , Wu Zherui , Just Pierre-Alexandre , Borghese Bruno , Ségal-Bendirdjian Evelyne , Gauchotte Guillaume , Gompel Anne , Forgez Patricia
Published: April 2023

Figure S2 shows the correlation of NTSR1 and NTSR3 z-score of the high-grade ovarian serous cystadenocarcinomas from the TCGA database and clinical parameters.
Figure S4 from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Authors: Trinh Anne , Trumpi Kari , De Sousa E Melo Felipe , Wang Xin , de Jong Joan H. , Fessler Evelyn , Kuppen Peter J.K. , Reimers Marlies S. , Swets Marloes , Koopman Miriam , Nagtegaal Iris D. , Jansen Marnix , Hooijer Gerrit K.J. , Offerhaus George J.A. , Kranenburg Onno , Punt Cornelis J. , Medema Jan Paul , Markowetz Florian , Vermeulen Louis
Published: April 2023

Fig. S4. Pathologist scoring of TMAs
Figure S3 from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Authors: Trinh Anne , Trumpi Kari , De Sousa E Melo Felipe , Wang Xin , de Jong Joan H. , Fessler Evelyn , Kuppen Peter J.K. , Reimers Marlies S. , Swets Marloes , Koopman Miriam , Nagtegaal Iris D. , Jansen Marnix , Hooijer Gerrit K.J. , Offerhaus George J.A. , Kranenburg Onno , Punt Cornelis J. , Medema Jan Paul , Markowetz Florian , Vermeulen Louis
Published: April 2023

Fig. S3. Overview of web-based classifier
supplemental legend from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Authors: Künkele Annette , Taraseviciute Agne , Finn Laura S. , Johnson Adam J. , Berger Carolina , Finney Olivia , Chang Cindy A. , Rolczynski Lisa S. , Brown Christopher , Mgebroff Stephanie , Berger Michael , Park Julie R. , Jensen Michael C.
Published: April 2023

supplemental legend
Supplemental Figure 2 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Authors: Dovedi Simon J. , Cheadle Eleanor J. , Popple Amy L. , Poon Edmund , Morrow Michelle , Stewart Ross , Yusko Erik C. , Sanders Catherine M. , Vignali Marissa , Emerson Ryan O. , Robins Harlan S. , Wilkinson Robert W. , Honeychurch Jamie , Illidge Timothy M.
Published: April 2023

Out-of-field tumor regression is a rare event following local single dose or fractionated RT.
Supplementary Data from Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Authors: Siravegna Giulia , Sartore-Bianchi Andrea , Nagy Rebecca J. , Raghav Kanwal , Odegaard Justin I. , Lanman Richard B. , Trusolino Livio , Marsoni Silvia , Siena Salvatore , Bardelli Alberto
Published: April 2023

Copy number plots from two pre-treatment HERACLES A samples. X axis represents chromosome (chr) number across the Guardant360 genomic footprint. Y axis represents observed copy number in plasma. Colored dots represent probe-specific copy number signals at each chromosomal position and light green horizontal line represents the sample-specific normalized diploid copy number. The 18 reported gene amplifications are labelled, including ERBB2 on chromosome 17. The sample represented in panel 2A is suggestive of chromosome 17 aneuploidy, as all 5' probe specific signals adjacent to and including ERBB2 are increased (ERBB2 observed pCN = 52.8). In contrast, panel 2B shows clear focal amplification of ERBB2 only (ERBB2 observed pCN = 7.7).
Supplemental Figure 1 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Authors: Dovedi Simon J. , Cheadle Eleanor J. , Popple Amy L. , Poon Edmund , Morrow Michelle , Stewart Ross , Yusko Erik C. , Sanders Catherine M. , Vignali Marissa , Emerson Ryan O. , Robins Harlan S. , Wilkinson Robert W. , Honeychurch Jamie , Illidge Timothy M.
Published: April 2023

Gating strategy for tumor cells and tumor infiltrating immune cells
Supplementary Data from Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Authors: Siravegna Giulia , Sartore-Bianchi Andrea , Nagy Rebecca J. , Raghav Kanwal , Odegaard Justin I. , Lanman Richard B. , Trusolino Livio , Marsoni Silvia , Siena Salvatore , Bardelli Alberto
Published: April 2023

ERBB2 pCN (pCN), RAS/RAF status and maximum mutant allele fraction (Max MAF) in 4,294 plasma samples from mCRC patients in the Guardant Health historical database. An observed pCN cutoff of 2.4 (>50th %ile) allowed for exclusion of 84% of all KRAS, NRAS, and BRAF driver mutations in the historical cohort. Dark blue dots - ERBB2 amplified and clonal RAS/RAF mutation positive; Light blue dots ERBB2 amplified and sub-clonal RAS/RAF mutation positive; Red dots - ERBB2 amplified and RAS/RAF mutation not detected.
Supplementary Table S1 from Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer
Authors: Tokunaga Ryuma , Xiu Joanne , Johnston Curtis , Goldberg Richard M. , Philip Philip A. , Seeber Andreas , Naseem Madiha , Lo Jae Ho , Arai Hiroyuki , Battaglin Francesca , Puccini Alberto , Berger Martin D. , Soni Shivani , Zhang Wu , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Baba Hideo , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

Supplementary Table S1. Antibodies in immunohistochemical analysis.
Supplemental Figures and Legends from Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target
Authors: Perales-Puchalt Alfredo , Svoronos Nikolaos , Rutkowski Melanie R. , Allegrezza Michael J. , Tesone Amelia J. , Payne Kyle K. , Wickramasinghe Jayamanna , Nguyen Jenny M. , O'Brien Shane W. , Gumireddy Kiranmai , Huang Qihong , Cadungog Mark G. , Connolly Denise C. , Tchou Julia , Curiel Tyler J. , Conejo-Garcia Jose R.
Published: April 2023

Supplemental Figure 1. (A) Cytotoxicity of FSHCER or mock transduced T-cells of OVCAR-3 luciferase tumor cells measured by luciferase detection after co-culture of 18 hours. (B) Gating strategy followed for the flow cytometry based cytotoxicity assay. After gating on the singlet cells we could gate the tumor cells and exclude T-cells by FSC and SSC (confirmed by the no Tcell control) and measure the percentage of living cells as double negatives from Annexin-V and 7AAD. Supplemental Figure 2. (A) immunohistochemistry showing a section CAOV3 tumor stained with FSHR18 antibody followed by secondary anti-mouse (FSHR18) or secondary alone (Negative). 20x, scale bar: 1 um. (B) Western blot and qPCR showing FSHR expression of different ovarian cancer and breast cancer tumor cell lines. (C) Tumor volume of three ovarian patient-derived xenograft tumors grown in the flank of NOD-SCID mice (n=2 mice per tumor, one case-one control, single experiment) injected intratumorally with 10 million FSHCER or mock transduced T-cells (arrows mark time of T-cell injection). Common axis used for easier cross comparison. Supplemental Figure 3. (A) FSHR mRNA of FACS-sorted ID8-Defb29/Vegf-a/Fshr from the peritoneal cavity of orthotopic ID8-Defb29/Vegf-a/Fshr-bearing mice treated with either FSHCER, mock transduced T-cells or PBS. (B) Normalized real-time quantitative-PCR of FSHR expression in the human healthy ovarian tissue shown in Figure 3A, a human serous ovarian carcinoma specimen and 2 additional cell lines. (C) Absence of expression of the FSHR in untransduced ID8-Defb29/Vegf-a cells, compared to FSHR-transduced clones (40 PCR cycles).
Supplementary Figure Captions from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Authors: Panek Rafal , Welsh Liam , Baker Lauren C.J. , Schmidt Maria A. , Wong Kee H. , Riddell Angela M. , Koh Dow-Mu , Dunlop Alex , Mcquaid Dualta , d'Arcy James A. , Bhide Shreerang A. , Harrington Kevin J. , Nutting Christopher M. , Hopkinson Georgina , Richardson Cheryl , Box Carol , Eccles Suzanne A. , Leach Martin O. , Robinson Simon P. , Newbold Kate L.
Published: April 2023

Supplementary Figure Captions
Supplementary Figure Legends from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Authors: Marachelian Araz , Villablanca Judith G. , Liu Cathy W. , Liu Betty , Goodarzian Fariba , Lai Hollie A. , Shimada Hiroyuki , Tran Hung C. , Parra Jaime A. , Gallego Richard , Bedrossian Nora , Young Sabrina , Czarnecki Scarlett , Kennedy Rebekah , Weiss Brian D. , Goldsmith Kelly , Granger Meaghan , Matthay Katherine K. , Groshen Susan , Asgharzadeh Shahab , Sposto Richard , Seeger Robert C.
Published: April 2023

Supplementary Figure Legends for A1-A3
Figure A2 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Authors: Marachelian Araz , Villablanca Judith G. , Liu Cathy W. , Liu Betty , Goodarzian Fariba , Lai Hollie A. , Shimada Hiroyuki , Tran Hung C. , Parra Jaime A. , Gallego Richard , Bedrossian Nora , Young Sabrina , Czarnecki Scarlett , Kennedy Rebekah , Weiss Brian D. , Goldsmith Kelly , Granger Meaghan , Matthay Katherine K. , Groshen Susan , Asgharzadeh Shahab , Sposto Richard , Seeger Robert C.
Published: April 2023

Change in BM and Blood NB5 ÃŽâ€�Ct for patients with progressive disease vs. non-progressive disease. Change in NB5 ÃŽâ€�Ct was assessed between pairs of time points where both NB5 ÃŽâ€�Ct and clinical disease assessments were performed. Observations are classified by whether there was clinical disease progression or not between the time points.
Figure S9 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Authors: Wildes Tyler J. , Grippin Adam , Dyson Kyle A. , Wummer Brandon M. , Damiani David J. , Abraham Rebecca S. , Flores Catherine T. , Mitchell Duane A.
Published: April 2023

IFN-g drives intratumoral HSPC differentiation.
Figure S7 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Figure 7 | PDX alteration status and p-S6 staining. (A) Nonsynonymous mutation distribution in PDX.155, PDX.180 and PDX.247 in genes involved in the frequently mutated PI3K/AKT/mTOR (blue) and MAPK pathway (yellow), ERBB family of receptor tyrosine kinases (green) and DNA repair pathway (red) as well as ARID1A and PALB2 are shown with OncoPrint. CNA in each mutated gene are added. (B) PDX.155, (C) PDX.180 and (D) PDX.247 representative p-S6 expression after 21 days of vehicle or AZD8055 treatment.
Supplemental Figure S8 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer
Authors: Mustafi Reba , Dougherty Urszula , Mustafi Devkumar , Ayaloglu-Butun Fatma , Fletcher Michelle , Adhikari Sarbani , Sadiq Farhana , Meckel Katherine , Haider Haider I. , Khalil Abdurahman , Pekow Joel , Konda Vani , Joseph Loren , Hart John , Fichera Alessandro , Li Yan Chun , Bissonnette Marc
Published: April 2023

. Note loss of ADAM17 staining in tumor epithelial cells in ADAM17Î"Î" tumors.
Figure S5_1 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Figure 5 | Clustering (n=106) and survival analysis (n=70) on kinome mutations and CNA. (A) Disease-specific survival of patients (n=70) grouped on ARID1A status, (B) PIK3CA status and (C) ARID1A + PIK3CA status. (D) Consensus clustering, with maximum group count set to 10 and clustering optimization with 1000 repetitions maximum, shows adding of tumors (n=106) as consensus index (horizontally) and empirical cumulative distribution (vertically) for 1-10 clusters. (E) Area under the curve plot of decrease in friction from 1-10 clusters. (F) Heatmap distribution of tumors in 8 clusters. (G) Disease-specific survival of patients (n=70) in 8 clusters, (H) cluster 3 vs. other clusters. (I) Disease-specific survival in advanced stage OCCC patients (FIGO 2C-4), Log rank (Mantel-Cox) was used for statistical analysis. (J) Nonsynonymous mutation distribution in genes involved in the frequently mutated PI3K/AKT/mTOR (blue) and MAPK pathway (yellow), ERBB family of receptor tyrosine kinases (green) and DNA repair pathway (red) as well as ARID1A and PALB2 are shown with OncoPrint. CNA in each mutated gene are added. The 106 OCCC tumors that were both kinome sequenced and SNP arrayed are shown on the horizontal axis grouped on tumor clusters and ordered on total event frequency in the subsequently altered pathways. (K) Oncoprint from advanced stage patients in cluster 3 vs. other clusters, shown on the horizontal axis grouped on tumor clusters and ordered on total event frequency in the subsequent altered pathways, ordered as aforementioned.
Supplemental Figure S5 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer
Authors: Mustafi Reba , Dougherty Urszula , Mustafi Devkumar , Ayaloglu-Butun Fatma , Fletcher Michelle , Adhikari Sarbani , Sadiq Farhana , Meckel Katherine , Haider Haider I. , Khalil Abdurahman , Pekow Joel , Konda Vani , Joseph Loren , Hart John , Fichera Alessandro , Li Yan Chun , Bissonnette Marc
Published: April 2023

A. Left panel Western diet; Right panel Western diet + INCB3619; B. Quantitative Ki67, *p<0.05, n = 4 mice/group.
Figure S3 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Figure 3 | Mutation distribution in OCCC. (A) Nonsynonymous mutation distribution in genes involved in the frequently mutated PI3K/AKT/mTOR (blue) and MAPK pathway (yellow), ERBB family of receptor tyrosine kinases (green) and DNA repair (red) pathway is shown. In this OncoPrint, kinome sequenced OCCC tumors are depicted on the horizontal axis and ordered on mutation frequency in the subsequent altered pathways, represented vertically on the right. ARID1A mutant tumors are displayed at the top. (B) BioVenn diagrams demonstrating overlap in ARID1A mutant tumors and PI3K/AKT/mTOR, MAPK and DNA repair pathway and ERBB family of receptor tyrosine kinases mutant tumors (n=103). On the right, PI3K/AKT/mTOR and MAPK pathway, the ERBB family of receptor tyrosine kinases and DNA repair pathway mutations within only ARID1A wildtype tumors (n=49) and only ARID1A mutant tumors (n=44). All data in A and B is derived from 122 kinome-sequenced OCCC tumors, overlap in BioVenn diagram circles is proportional to group overlap.
Supplemental Figure S3 and Supplemental Figure S4 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer
Authors: Mustafi Reba , Dougherty Urszula , Mustafi Devkumar , Ayaloglu-Butun Fatma , Fletcher Michelle , Adhikari Sarbani , Sadiq Farhana , Meckel Katherine , Haider Haider I. , Khalil Abdurahman , Pekow Joel , Konda Vani , Joseph Loren , Hart John , Fichera Alessandro , Li Yan Chun , Bissonnette Marc
Published: April 2023

Supplemental Figure S3. Marimastat suppresses colonic EGFR signals. Mice received vehicle or marimastat and were fed WD. After 2 wks, colonic proteins measured by WB. A. Alzet pump. B. Protocol. C. EGFR signals. D. Quantitative levels (*p<0.05, phospho-protein levels compared to WD alone; n=4 per group); Supplemental Figure S4. INCB3619 inhibits ADAM17 activity in vitro and in vivo. A. INCB3619 inhibits recombinant ADAM17 activity. B. Dietary INCB3619 inhibits intestinal mucosal ADAM17 activity.
Supplementary Table S2 from Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment
Authors: Martinez-Garcia Elena , Lesur Antoine , Devis Laura , Cabrera Silvia , Matias-Guiu Xavier , Hirschfeld Marc , Asberger Jasmin , van Oostrum Jan , Casares de Cal María de los Ángeles , Gómez-Tato Antonio , Reventos Jaume , Domon Bruno , Colas Eva , Gil-Moreno Antonio
Published: April 2023

Supplementary Table S2. List of precursors and related fragment ions extracted from PRM acquisition.
Supplementary Fig 8 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 8
Supplementary Table S1 from Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment
Authors: Martinez-Garcia Elena , Lesur Antoine , Devis Laura , Cabrera Silvia , Matias-Guiu Xavier , Hirschfeld Marc , Asberger Jasmin , van Oostrum Jan , Casares de Cal María de los Ángeles , Gómez-Tato Antonio , Reventos Jaume , Domon Bruno , Colas Eva , Gil-Moreno Antonio
Published: April 2023

Supplementary Table S1. Clinico-pathological characteristics of the 116 women enrolled in the study.
Supplementary Fig 5 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 5
Supplementary Fig 3 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 3
Supplementary Table S6 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Authors: Siemeister Gerhard , Mengel Anne , Fernández-Montalván Amaury E. , Bone Wilhelm , Schröder Jens , Zitzmann-Kolbe Sabine , Briem Hans , Prechtl Stefan , Holton Simon J. , Mönning Ursula , von Ahsen Oliver , Johanssen Sandra , Cleve Arwed , Pütter Vera , Hitchcock Marion , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Crystallographic data
Supplementary Table S5 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Authors: Siemeister Gerhard , Mengel Anne , Fernández-Montalván Amaury E. , Bone Wilhelm , Schröder Jens , Zitzmann-Kolbe Sabine , Briem Hans , Prechtl Stefan , Holton Simon J. , Mönning Ursula , von Ahsen Oliver , Johanssen Sandra , Cleve Arwed , Pütter Vera , Hitchcock Marion , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Exposure data from xenograft studies
Supplementary Table S4 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Authors: Siemeister Gerhard , Mengel Anne , Fernández-Montalván Amaury E. , Bone Wilhelm , Schröder Jens , Zitzmann-Kolbe Sabine , Briem Hans , Prechtl Stefan , Holton Simon J. , Mönning Ursula , von Ahsen Oliver , Johanssen Sandra , Cleve Arwed , Pütter Vera , Hitchcock Marion , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

In vitro combination results
Supplementary Fig 10 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 10
Supplementary Data from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Includes Sup Tab 1-2
Supplementary Table S2 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Authors: Weigelt Britta , Comino-Méndez Iñaki , de Bruijn Ino , Tian Lei , Meisel Jane L. , García-Murillas Isaac , Fribbens Charlotte , Cutts Ros , Martelotto Luciano G. , Ng Charlotte K.Y. , Lim Raymond S. , Selenica Pier , Piscuoglio Salvatore , Aghajanian Carol , Norton Larry , Murali Rajmohan , Hyman David M. , Borsu Laetitia , Arcila Maria E. , Konner Jason , Reis-Filho Jorge S. , Greenberg Roger A. , Robson Mark E. , Turner Nicholas C.
Published: April 2023

Sequencing statistics and non-synonymous somatic mutations identified in cfDNA and tumor tissue of ovarian and breast cancer patients included in this study.
Supplementary Table S1 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Authors: Weigelt Britta , Comino-Méndez Iñaki , de Bruijn Ino , Tian Lei , Meisel Jane L. , García-Murillas Isaac , Fribbens Charlotte , Cutts Ros , Martelotto Luciano G. , Ng Charlotte K.Y. , Lim Raymond S. , Selenica Pier , Piscuoglio Salvatore , Aghajanian Carol , Norton Larry , Murali Rajmohan , Hyman David M. , Borsu Laetitia , Arcila Maria E. , Konner Jason , Reis-Filho Jorge S. , Greenberg Roger A. , Robson Mark E. , Turner Nicholas C.
Published: April 2023

List of 143 genes included in the targeted capture massively parallel sequencing assay.
Supplementary Figure S4 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Authors: Weigelt Britta , Comino-Méndez Iñaki , de Bruijn Ino , Tian Lei , Meisel Jane L. , García-Murillas Isaac , Fribbens Charlotte , Cutts Ros , Martelotto Luciano G. , Ng Charlotte K.Y. , Lim Raymond S. , Selenica Pier , Piscuoglio Salvatore , Aghajanian Carol , Norton Larry , Murali Rajmohan , Hyman David M. , Borsu Laetitia , Arcila Maria E. , Konner Jason , Reis-Filho Jorge S. , Greenberg Roger A. , Robson Mark E. , Turner Nicholas C.
Published: April 2023

Variant allele frequencies of somatic mutations in the longitudinal plasma samples from breast cancer patient L031 as defined by amplicon re-sequencing.
Supplementary Figure S3 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Authors: Weigelt Britta , Comino-Méndez Iñaki , de Bruijn Ino , Tian Lei , Meisel Jane L. , García-Murillas Isaac , Fribbens Charlotte , Cutts Ros , Martelotto Luciano G. , Ng Charlotte K.Y. , Lim Raymond S. , Selenica Pier , Piscuoglio Salvatore , Aghajanian Carol , Norton Larry , Murali Rajmohan , Hyman David M. , Borsu Laetitia , Arcila Maria E. , Konner Jason , Reis-Filho Jorge S. , Greenberg Roger A. , Robson Mark E. , Turner Nicholas C.
Published: April 2023

Repertoire of non-synonymous somatic mutations in plasma DNA derived from breast cancer patients with BRCA1/2 germline mutations previously treated with platinum-based chemotherapy and/or PARP inhibitors.
Table S1 from BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models
Authors: Ganaie Arsheed A. , Beigh Firdous H. , Astone Matteo , Ferrari Marina G. , Maqbool Raihana , Umbreen Syed , Parray Aijaz S. , Siddique Hifzur R. , Hussain Tabish , Murugan Paari , Morrissey Colm , Koochekpour Shahriar , Deng Yibin , Konety Badrinath R. , Hoeppner Luke H. , Saleem Mohammad
Published: April 2023

Supplementary Table 1. Sequence of primers used for ChIP analysis of PTEN, INK4A/p16 and GAPDH promoters.
Supplemental legend from BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models
Authors: Ganaie Arsheed A. , Beigh Firdous H. , Astone Matteo , Ferrari Marina G. , Maqbool Raihana , Umbreen Syed , Parray Aijaz S. , Siddique Hifzur R. , Hussain Tabish , Murugan Paari , Morrissey Colm , Koochekpour Shahriar , Deng Yibin , Konety Badrinath R. , Hoeppner Luke H. , Saleem Mohammad
Published: April 2023

Supplemental legend
Supplementary Figure S1 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Authors: Weigelt Britta , Comino-Méndez Iñaki , de Bruijn Ino , Tian Lei , Meisel Jane L. , García-Murillas Isaac , Fribbens Charlotte , Cutts Ros , Martelotto Luciano G. , Ng Charlotte K.Y. , Lim Raymond S. , Selenica Pier , Piscuoglio Salvatore , Aghajanian Carol , Norton Larry , Murali Rajmohan , Hyman David M. , Borsu Laetitia , Arcila Maria E. , Konner Jason , Reis-Filho Jorge S. , Greenberg Roger A. , Robson Mark E. , Turner Nicholas C.
Published: April 2023

Repertoire of non-synonymous somatic mutations in tumors and plasma DNA derived from ovarian cancer patients with BRCA1/2 germline mutations resistant/ refractory to platinum-based chemotherapy.
Supplementary Text from Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Authors: Garlan Fanny , Laurent-Puig Pierre , Sefrioui David , Siauve Nathalie , Didelot Audrey , Sarafan-Vasseur Nasrin , Michel Pierre , Perkins Geraldine , Mulot Claire , Blons Hélène , Taieb Julien , Di Fiore Frederic , Taly Valerie , Zaanan Aziz
Published: April 2023

Supplementary text, Tables and supplementary figure legends Supplementary Table 1. Comparison of clinical variables between patients with no detectable ctDNA versus patients with detectable ctDNA at baseline. Supplementary Table 2: Different multivariate models Supplementary Table 3: Impact on progression free survival and overall survival of ctDNA variations observed between C0 and C2or1 and adjustment on variables for the subgroup of patient with ctDNA detectable at both C0 and C2or1.
FigureS4 from Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Authors: Garlan Fanny , Laurent-Puig Pierre , Sefrioui David , Siauve Nathalie , Didelot Audrey , Sarafan-Vasseur Nasrin , Michel Pierre , Perkins Geraldine , Mulot Claire , Blons Hélène , Taieb Julien , Di Fiore Frederic , Taly Valerie , Zaanan Aziz
Published: April 2023

Supplementary Figure 4. Impact on Progression free survival (PFS) of the slope of decrease of ctDNA concentration (SlopeÃ¢Ë†â€ ctDNA, {greater than or equal to}80% or <80%) in the D{greater than or equal to}0.1ng/mL group.
FigureS3 from Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Authors: Garlan Fanny , Laurent-Puig Pierre , Sefrioui David , Siauve Nathalie , Didelot Audrey , Sarafan-Vasseur Nasrin , Michel Pierre , Perkins Geraldine , Mulot Claire , Blons Hélène , Taieb Julien , Di Fiore Frederic , Taly Valerie , Zaanan Aziz
Published: April 2023

Supplementary Figure 3. Progression free survival (PFS, panel A) and overall survival (OS, Panel B) of metastatic colorectal cancer patients according to variations of ctDNA concentration categorized in three groups: decreasing group with a ctDNA normalization at C2or1 (D{less than or equal to}0.1ng/mL, blue), decreasing group without a ctDNA normalization at C2or1 (D>0.1 ng/mL, yellow) and the increasing group with a higher ctDNA concentration at C2or1 than at C0 (I>0.1 ng/mL, red).
FigureS1 from Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Authors: Garlan Fanny , Laurent-Puig Pierre , Sefrioui David , Siauve Nathalie , Didelot Audrey , Sarafan-Vasseur Nasrin , Michel Pierre , Perkins Geraldine , Mulot Claire , Blons Hélène , Taieb Julien , Di Fiore Frederic , Taly Valerie , Zaanan Aziz
Published: April 2023

Supplementary Figure 1. Impact of baseline ctDNA concentration on overall survival (OS) in the subgroup of patients included before the 1st line of treatment (n=68).
Supplementary Figure 1 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Authors: Shah Manish A. , Starodub Alexander , Sharma Sunil , Berlin Jordan , Patel Manish , Wainberg Zev A. , Chaves Jorge , Gordon Michael , Windsor Kevin , Brachmann Carrie Baker , Huang Xi , Vosganian Greg , Maltzman Julia D. , Smith Victoria , Silverman Jeffrey A. , Lenz Heinz-Josef , Bendell Johanna C.
Published: April 2023

Full study schema (ClinicalTrials.gov Identifier: NCT01803282)
Table S1, Table S2 from Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Authors: Meulendijks Didier , Jacob Wolfgang , Voest Emile E. , Mau-Sorensen Morten , Martinez-Garcia Maria , Taus Alvaro , Fleitas Tania , Cervantes Andres , Lolkema Martijn P. , Langenberg Marlies H.G. , De Jonge Maja J. , Sleijfer Stefan , Han Ji-Youn , Calles Antonio , Felip Enriqueta , Kim Sang-We , Schellens Jan H.M. , Wilson Sabine , Thomas Marlene , Ceppi Maurizio , Meneses-Lorente Georgina , James Ian , Vega-Harring Suzana , Dua Rajiv , Nguyen Maitram , Steiner Lori , Adessi Celine , Michielin Francesca , Bossenmaier Birgit , Weisser Martin , Lassen Ulrik N.
Published: April 2023

Supplementary Table 1 Downregulation of HER3 membrane protein expression in skin biopsies following treatment with lumretuzumab and cetuximab or erlotinib Supplementary Table 2 Change of tumor biomarkers in tumor biopsies following treatment with lumretuzumab and cetuximab or erlotinib
Figure S8 from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

AXL as a therapeutic biomarker
Figure S7 from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

The prognostic value of the signature
Figure S6 from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

Gene mutations among HGSOCs reveal DNAH5 as a FT-derived HGSOC exclusively mutated gene
SUPPLEMENTAL DATA from Jab1/Csn5–Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress
Authors: Zhou Fuling , Pan Yunbao , Wei Yongchang , Zhang Ronghua , Bai Gaigai , Shen Qiuju , Meng Shan , Le Xiao-Feng , Andreeff Michael , Claret Francois X.
Published: April 2023

Supplemental Table 1 Clinical characteristics of AML-M5 patients (n=60) Supplemental Table 2 Summary of abnormal cytogenetic results Supplemental Figure 1. (a) ROS levels were examined in leukemia patients. Supplemental Figure 2. Association between ELN risk and overall survival. Supplemental Figure 3. Jab1 regulates Trx expression in AML. Supplemental Figure 4. (a) Trx knockdown did not change the expression of Jab1 in AML cell lines. Supplemental Figure 5. (a) Normal HS-5 bone marrow cells were transfected with His-Jab1 for 48 h, and then plated in six-well plates for clonogenic assay in RPMI-1640 medium with 10% FBS.
Figure S1 from Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses
Authors: Hao Dapeng , Li Jingjing , Jia Shanshan , Meng Yuan , Zhang Chao , Wang Li , Di Li-jun
Published: April 2023

Integrative analysis of the transcriptome difference between FT and OSE
Supplementary data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Authors: Bansal Nitu , Bartucci Monica , Yusuff Shamila , Davis Stephani , Flaherty Kathleen , Huselid Eric , Patrizii Michele , Jones Daniel , Cao Liangxian , Sydorenko Nadiya , Moon Young-Choon , Zhong Hua , Medina Daniel , Kerrigan John , Stein Mark N. , Kim Isaac Y. , Davis Thomas W. , DiPaola Robert S. , Bertino Joseph , Sabaawy Hatem E.
Published: April 2023

Supplementary data Figure S1. Functional role(s) of BMI-1 in PCa. Figure S2. BMI-1 expression in subpopulations of DU145 cells. Figure S3. Pharmacological inhibition of BMI-1. Figure S4. Molecular and cellular effects of pharmacological targeting of BMI-1. Figure S5. Examining BMI-1 inhibitors in toxicological assays and effects on normal cells. Figure S6. Toxicity effects of C-209 and CHX on adult and embryo zebrafish. Figure S7. BMI-1 inhibition effect on the normal prostate and hematopoietic system. Figure S8. Representative images of BMI-1 expression in primary PCa samples. Figure S9. Xenografts of human primary PCa cells in embryonic zebrafish. Figure S10. Xenografts of primary PCa tissue in zebrafish embryos. Figure S11. Toxicology assays of chemotherapy and BMI-1 inhibitors in embryonic zebrafish. Figure S12. Anti-tumor activity of BMI-1 inhibitors. Figure S13. Representative H&E staining of mouse xenograft sections indicating the histological effects of treatments. Figure S14. In vivo pharmacological targeting of BMI-1 in androgen independent DU145 and androgen sensitive 22rv1 PCa mouse xenografts. Figure S15. Colony-formation frequency evaluated by dilution analysis of xenograft-derived cells from untreated mice and mice treated with C-209 60mg/kg/day. Figure S16. BMI-1 inhibition effects on androgen-dependent and -independent cells.
Supplementary Data and Methods from The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells
Authors: Yang Zhao , He Luyun , Lin Kaisu , Zhang Yun , Deng Aihua , Liang Yong , Li Chong , Wen Tingyi
Published: April 2023

Supplemental Materials show that KMT1A was highly expressed in BCSCs compared with either BCNSCs or normal bladder tissue, and positively regulated the self-renewal and tumorigenicity of human BCSCs via KMT1A-GATA3-STAT3 circuit.
Table S2 from Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling
Authors: Wang Guangzhi , Shen Jia , Sun Jiahang , Jiang Zhenfeng , Fan Jiabing , Wang Hongjun , Yu Shan , Long Yu , Liu Yi , Bao Hongbo , Zhang Kelvin Xi , Han Ke , Zhu Minwei , Zheng Yongri , Lin Zhiguo , Jiang Chuanlu , Guo Mian
Published: April 2023

Clinicopathological characteristics
Supplementary table 5 from Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis
Authors: Thomas Laura E. , Hurley Joanna J. , Meuser Elena , Jose Sian , Ashelford Kevin E. , Mort Matthew , Idziaszczyk Shelley , Maynard Julie , Brito Helena Leon , Harry Manon , Walters Angharad , Raja Meera , Walton Sarah-Jane , Dolwani Sunil , Williams Geraint T. , Morgan Meleri , Moorghen Morgan , Clark Susan K. , Sampson Julian R.
Published: April 2023

Summary of the mutations identified by exome analysis and targeted screening of KRAS, PTCHD2, ERBB3 and PLCL1. Patterned shading indicates duplicate adenomas.
Supplementary table 4 from Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis
Authors: Thomas Laura E. , Hurley Joanna J. , Meuser Elena , Jose Sian , Ashelford Kevin E. , Mort Matthew , Idziaszczyk Shelley , Maynard Julie , Brito Helena Leon , Harry Manon , Walters Angharad , Raja Meera , Walton Sarah-Jane , Dolwani Sunil , Williams Geraint T. , Morgan Meleri , Moorghen Morgan , Clark Susan K. , Sampson Julian R.
Published: April 2023

Database of somatic APC mutations reported in FAP and MAP duodenal and colorectal adenomas. NA, Not available. NI, Not identified
Supplementary table 3 from Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis
Authors: Thomas Laura E. , Hurley Joanna J. , Meuser Elena , Jose Sian , Ashelford Kevin E. , Mort Matthew , Idziaszczyk Shelley , Maynard Julie , Brito Helena Leon , Harry Manon , Walters Angharad , Raja Meera , Walton Sarah-Jane , Dolwani Sunil , Williams Geraint T. , Morgan Meleri , Moorghen Morgan , Clark Susan K. , Sampson Julian R.
Published: April 2023

Summary of the 62 recurrently mutated genes in the exome dataset (supplementary table 2) and the number of mutations identified in each gene. Total numbers of variants in each gene take into account any mutations identified in duplicate adenomas.
Supplementary table 2 from Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis
Authors: Thomas Laura E. , Hurley Joanna J. , Meuser Elena , Jose Sian , Ashelford Kevin E. , Mort Matthew , Idziaszczyk Shelley , Maynard Julie , Brito Helena Leon , Harry Manon , Walters Angharad , Raja Meera , Walton Sarah-Jane , Dolwani Sunil , Williams Geraint T. , Morgan Meleri , Moorghen Morgan , Clark Susan K. , Sampson Julian R.
Published: April 2023

Summary of all validated variants identified by exome sequencing. Patterned shading indicates duplicate adenomas.
Figure S2 from Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling
Authors: Wang Guangzhi , Shen Jia , Sun Jiahang , Jiang Zhenfeng , Fan Jiabing , Wang Hongjun , Yu Shan , Long Yu , Liu Yi , Bao Hongbo , Zhang Kelvin Xi , Han Ke , Zhu Minwei , Zheng Yongri , Lin Zhiguo , Jiang Chuanlu , Guo Mian
Published: April 2023

CypA upregulation promotes self-renewal and proliferation of GICs
Figure S1 from Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling
Authors: Wang Guangzhi , Shen Jia , Sun Jiahang , Jiang Zhenfeng , Fan Jiabing , Wang Hongjun , Yu Shan , Long Yu , Liu Yi , Bao Hongbo , Zhang Kelvin Xi , Han Ke , Zhu Minwei , Zheng Yongri , Lin Zhiguo , Jiang Chuanlu , Guo Mian
Published: April 2023

Overexpression of CypA enhances stemness of GICs
Supplementary Figure 1 from Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis
Authors: Thomas Laura E. , Hurley Joanna J. , Meuser Elena , Jose Sian , Ashelford Kevin E. , Mort Matthew , Idziaszczyk Shelley , Maynard Julie , Brito Helena Leon , Harry Manon , Walters Angharad , Raja Meera , Walton Sarah-Jane , Dolwani Sunil , Williams Geraint T. , Morgan Meleri , Moorghen Morgan , Clark Susan K. , Sampson Julian R.
Published: April 2023

Histogram showing number of validated protein changing somatic variants identified per adenoma.
Supplementary Figure S5: Ipilimumab increases the frequency of CD3+CD8+ T cells but not CD3-CD8+CD56+ NK cells in human melanoma from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Authors: Sharma Anu , Subudhi Sumit K. , Blando Jorge , Scutti Jorge , Vence Luis , Wargo Jennifer , Allison James P. , Ribas Antoni , Sharma Padmanee
Published: April 2023

Tumor infiltrating cells from paired melanoma tissue (N=5 pre-Ipi; N=5 post-Ipi) were analyzed by CyTOF. The impact of ipilimumab on the intratumoral frequency of A) CD3+CD8+ T cells, and B) CD3-CD8+CD56+ NK cells. Each plot shows mean with SD, and each symbol represents an individual patient. Statistical significance is defined as P < 0.05.
Supplementary Figure 2 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo
Authors: Morrow James J. , Mendoza Arnulfo , Koyen Allyson , Lizardo Michael M. , Ren Ling , Waybright Timothy J. , Hansen Ryan J. , Gustafson Daniel L. , Zhou Ming , Fan Timothy M. , Scacheri Peter C. , Khanna Chand
Published: April 2023

Highly metastatic osteosarcoma cells activate the mTOR pathway during metastatic progression
Supplementary Figure S4: Timing of post-ipilimumab biopsy does not impact immune infiltration from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Authors: Sharma Anu , Subudhi Sumit K. , Blando Jorge , Scutti Jorge , Vence Luis , Wargo Jennifer , Allison James P. , Ribas Antoni , Sharma Padmanee
Published: April 2023

Scatter plots representing correlation analysis between timing of the post-Ipi treatment biopsy and immune infiltration (CD4, CD8 and FOXP3) in human melanoma tumors for A) ipilimumab, and B) tremelimumab. Each dot represents an individual patient, and statistical significance is defined as P < 0.05. The slope of the plot is given by the Spearman rank correlation r.
Supplementary Figure 1 from mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo
Authors: Morrow James J. , Mendoza Arnulfo , Koyen Allyson , Lizardo Michael M. , Ren Ling , Waybright Timothy J. , Hansen Ryan J. , Gustafson Daniel L. , Zhou Ming , Fan Timothy M. , Scacheri Peter C. , Khanna Chand
Published: April 2023

5' UTR structures of BONCAT identified proteins
Supplementary Figure S2: Effect of ipilimumab on CD4+ cells and CD8+ cells in bladder and prostate tumors from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Authors: Sharma Anu , Subudhi Sumit K. , Blando Jorge , Scutti Jorge , Vence Luis , Wargo Jennifer , Allison James P. , Ribas Antoni , Sharma Padmanee
Published: April 2023

A) Stage-matched untreated and Ipi-treated bladder tumors (N=9), and B) prostate tumors (N=17) were analyzed by IHC for the presence of CD4+ and CD8+ cells. Each plot shows mean with SD, and each symbol represents an individual patient. Statistical significance is defined as P < 0.05.
Supplementary Figure 7 from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Authors: Horikawa Naoki , Abiko Kaoru , Matsumura Noriomi , Hamanishi Junzo , Baba Tsukasa , Yamaguchi Ken , Yoshioka Yumiko , Koshiyama Masafumi , Konishi Ikuo
Published: April 2023

Pictures of HM-1 subcutaneous tumors treated by anti-Gr-1 antibody
Supplementary Figure 6 from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Authors: Horikawa Naoki , Abiko Kaoru , Matsumura Noriomi , Hamanishi Junzo , Baba Tsukasa , Yamaguchi Ken , Yoshioka Yumiko , Koshiyama Masafumi , Konishi Ikuo
Published: April 2023

Quantitative PCR analysis of HM-1 and Vegfa knockdown tumors
Figure Legends from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Authors: Sharma Anu , Subudhi Sumit K. , Blando Jorge , Scutti Jorge , Vence Luis , Wargo Jennifer , Allison James P. , Ribas Antoni , Sharma Padmanee
Published: April 2023

Figure Legends for Supplementary Figures
Supplementary Figure 5 from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Authors: Horikawa Naoki , Abiko Kaoru , Matsumura Noriomi , Hamanishi Junzo , Baba Tsukasa , Yamaguchi Ken , Yoshioka Yumiko , Koshiyama Masafumi , Konishi Ikuo
Published: April 2023

Expression analysis of HM-1 shVegf-a cells
Figure S1, Table S1-S3 from Detection of Head and Neck Cancer in Surgical Specimens Using Quantitative Hyperspectral Imaging
Authors: Lu Guolan , Little James V. , Wang Xu , Zhang Hongzheng , Patel Mihir R. , Griffith Christopher C. , El-Deiry Mark W. , Chen Amy Y. , Fei Baowei
Published: April 2023

Supplementary figure and tables
Supplementary Figure 1 from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Authors: Horikawa Naoki , Abiko Kaoru , Matsumura Noriomi , Hamanishi Junzo , Baba Tsukasa , Yamaguchi Ken , Yoshioka Yumiko , Koshiyama Masafumi , Konishi Ikuo
Published: April 2023

VEGF signature scores of clinical samples
Supplementary Data from Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice
Authors: Jung Kwang Hwa , Yoo Wonbeak , Stevenson Heather L. , Deshpande Dipti , Shen Hong , Gagea Mihai , Yoo Suk-Young , Wang Jing , Eckols T. Kris , Bharadwaj Uddalak , Tweardy David J. , Beretta Laura
Published: April 2023

Supplementary Data from Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice
Supplementary Data-Data from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Authors: Rojas Elizabeta A. , Corchete Luis Antonio , San-Segundo Laura , Martínez-Blanch Juan F. , Codoñer Francisco M. , Paíno Teresa , Puig Noemí , García-Sanz Ramón , Mateos María Victoria , Ocio Enrique M. , Misiewicz-Krzeminska Irena , Gutiérrez Norma C.
Published: April 2023

Supplementary methods, tables and references.
Supplemental Table S5. from The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Authors: Stover Daniel G. , Coloff Jonathan L. , Barry William T. , Brugge Joan S. , Winer Eric P. , Selfors Laura M.
Published: April 2023

Signature Association with Pathologic Complete Response by Sugroup